WORLD JOURNAL OF SURGICAL ONCOLOGY

Full list of author information is available at the end of the articlelung adenocarcinomas [1], thus improving patient survival [2]. Based on a randomized trial performed in 1995, the current standard surgical treatment for clinical stage IA non-small cell lung cancer (NSCLC) is lobectomy with prognosis: in most cases their pathologic features indicate they are minimally invasive [4-8], whereas mixed GGOs or pure solid tumors are more prone to lymph node metastasis. Since there is no well-established means of predicting lymph node metastasis, systematic lymph node dissection for clinical stage T1aN0M0 lung adenocarcinomas is con-* Correspondence